-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
Denali Therapeutics today announced new interim results from a Phase 1/2 clinical trial of its investigational enzyme replacement therapy DNL310 in mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome)MPS II is a rare neurodegenerative lysosomal storage disease caused by mutations in the gene encoding human idose-2-sulfatase (IDS), affecting more than 2,000 patients worldwide
▲Denali’s transporter platform (Image source: Denali’s official website)
WuXi AppTec provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, covering chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and production and other fields